← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Arrevus, Inc.
Durham, NC
$4,236,542
Total funding
9
Grants
Funding over time
peak $1.3M · FY2018–23$2M$1.5M$1M$500K$0
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$4,236,542 · 9
By mechanism
R41$2,527,834 · 8
R42$1,708,708 · 1
Investigators at Arrevus, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
Development of a Designer Proline-rich antimicrobial peptide Chaperone protein inhibitor (DPC) for treating multi-drug resistant bacteremia$738,606
R42 · FY2019 · AI
Development of a Designer Proline-rich antimicrobial peptide Chaperone protein inhibitor (DPC) for treating multi-drug resistant bacteremia$672,647
R42 · FY2020 · AI
Engineered adipokine receptor inhibitor for the treatment of triple negative breast cancer in obese patients$400,000
R41 · FY2021 · CA
Leptin Receptor Agonist to Treat Sleep Disordered Breathing$319,944
R41 · FY2023 · HL
Leptin Receptor Agonist as a Novel Prevention of Opioid Induced Respiratory Depression$318,971
R41 · FY2022 · DA
Development of a Designer Proline-rich antimicrobial peptide Chaperone protein inhibitor (DPC) for treating multi-drug resistant wound infections$300,000
R41 · FY2018 · AI
Development of a Designer Proline-rich antimicrobial peptide Chaperone protein inhibitor (DPC) for treating sepsis$299,999
R41 · FY2020 · AI
Development of a predictive moderate throughput assay to screen novel Designer Proline-rich antimicrobial peptide Chaperone protein inhibitors (DPCs) against multi-drug resistant pathogen$299,248
R41 · FY2019 · AI
Development of a Designer Proline-rich antimicrobial peptide Chaperone protein inhibitor (DPC) for treating multi-drug resistant bacteremia$297,455
R42 · FY2018 · AI
Development of a Designer Proline-rich antimicrobial peptide Chaperone protein inhibitor (DPC) for treating multi-drug resistant urinary tract infections$295,171
R41 · FY2018 · AI
Use of a Designer Proline-rich antimicrobial peptide Chaperone protein inhibitor (DPC) for treating antibiotic resistant pneumonia$294,501
R41 · FY2019 · AI